4SC AG, which is working on epigenetic cancer therapies, has appointed Jason Loveridge as its new chief executive. Dr Loveridge has worked in senior management positions in the life science sector and as an investment professional for more than 20 years. He graduated in biochemistry and microbiology from the University of New South Wales in Australia and holds a PhD in biochemistry from the University of Adelaide.
4SC announced the appointment on 21 September 2016.
Copyright 2016 Evernow Publishing Ltd